[Biochem. J. 61, 116 (1955) ] for creatine kinase is usually suppressed by including an adenylate kinase inhibitor, AMP. We studied the kinetics and compared the inhibition capacities of AMP and diadenosine pentaphosphate.
Both are competitive inhibitors, AMP being markedly weaker, with a K, of about 300 tmol/liter for adenylate kinase from erythrocyte, muscle, and liver. AMP also weakly inhibits creatine kinase. Diadenosine pentaphosphate inhibits erythrocyte arid muscle adenylate kinase strongly (K, about 0.03 tmol/liter), the liver isoenzyme less strongly (K, about 3 zmoI/liter), and has no effect on creatine kinase up to 100 zmol/liter. All three adenylate kinases may be present in a patient's serum, causing sample blanks to be high in a creatine kinase assay that lacks inhibitors. In acute hepatic damage, liver adenylate kinase activity in serum can be grossly increased. Use of sufficient diadenosine pentaphosphate alone for complete inhibition is relatively expensive. Consequently, we recommend a combination of both inhibitors. Diadenosine pentaphosphate, 10 tmol, combined with 5 mmol of AMP per liter inhibits adenylate kinase from erythrocytes and muscle by 97% and from liver by 95%.
There may be numerous interferences with the measurement of creatine kinase (ATP:creatine Nphosphotransferase; EC 2.7.3.2) activity (3) when the creatine phosphate -creatine reaction coupled with hexokinase (EC 2.7.1.1) and glucose-6-phosphate dehydrogenase (EC 1.1.1.49) is used (1) .
For example, adenylate kinase (ATP:AMP phosphotransferase; EC 2.7.4.3), which catalyzes the reaction adenylate kinase 2ADP ==± ATP+AMP can also act on the ADP, the substrate in the creatine kinase assay, to generate additional amounts of ATP and thus increase the apparent creatine kinase activity.
Adenylate kinase is widely distributed among the different organs, with decreasing activities in the sequence: skeletal muscle, brain, liver, heart, kidney, small intestine, spleen, and lung (4). In sera of healthy individuals the adenylate kinase activity ranges between 0-50 U/liter at 25 #{176}C (5), but is markedly increased in hemolytic specimens.
Interference by adenylate kinase with the creatine kinase assay can be decreased by inhibiting adenylate kinase. Usually AMP has been used for this (1, (6) (7) (8) (9) ), but it not only inhibits adenylate kinase but also creatine kinase to some extent (10). Diadenosine pentaphosphate, a recently described potent inhibitor of adenylate kinase (2), selectively inhibits the enzyme of muscle and erythrocyte type at very low concentrations (10 mol/ liter); the liver and the kidney enzyme are less affected (11). Similar isoenzyme-specific inhibition of adenylate kinase has been also described for other compounds (12) .
We compared the usefulness of AMP and diadenosine pentaphosphate as inhibitors of adenylate kinase in the creatine kinase assay, considering the selective inhibitory efficacy of diadenosine pentaphosphate and the incidence of the liver adenylate kinase isoenzyme in serum in various diseases.
Materials and Methods
Erythrocyte adenylate kinase was obtained from erythrocytes of healthy individuals. The erythrocytes were washed five times with physiological saline and then hemolyzed by adding equal volumes of doubly distilled water. The hemolysate was centrifuged at 15 000 X g for 2 mi In the clear supernates the hemoglobin concentration ranged between 110 and 140 g/liter of supernate.
Liver adenylate kinase was obtained from human biopsy material. A fresh sample of liver was weighed, homogenized in a chilled homogenizer (Heidolph Elektro KG, Kelheim, Germany; Typ RZR I) with 20 volumes of ice-cold physiological saline for 1 mm, and centrifuged at 15 000 X g for 2 mm. The adenylate kinase activity of the supernates ranged from 300 to 500 U/liter at 25 #{176}C; the hemoglobin concentration was less than 20 mg per 100 ml of supernatant fluid. Adenylate kinase from rabbit muscle and diadenosine pentaphosphate [P1,P5-di(adenosmne-5')pentaphos- 
Results

Adenylate Kinase Activity in Serum in Health and Disease
To evaluate the potential adenylate kinase interference with the creatine kinase assay, we studied adenylate kinase activity in serum of healthy individuals and patients with muscle and liver damage.
Our reference group comprised 184 male and 204 female inpatients having normal serum creatine kinase, aspartate aminotransferase, and lactate dehydrogenase activities. In both groups the adenylate kinase values estimated at optimum conditions and at 25 #{176}C showed nongaussian distributions.
The 95% range of the reference values, calculated therefore by nonparametric statistics, was 8-53 U/liter for men and 8-47 U/liter for women.
To predict an increase in adenylate kinase activity by means of other enzyme activities is very difficult. We often observed normal adenylate kinase activities in sera of patients with various muscle lesions, even if the creatine kinase activities were highly increased, up to 1000 U/liter at 25 #{176}C. Serial determinations in the course of acute myocardial infarctions yielded, during the first post-episode days, consistently normal adenylate kinase activities in half of the patients (peak creatine kinase values between 660 and 1690 U/liter at 25 #{176}C); in the remaining cases we observed only slight and transitory elevations. The maximum values were between 71 and 83 U/liter; values for creatine kinase activity simultaneously were scattered between 520 and 730 U/liter. In hemolytic samples adenylate kinase activity may gen- However, it is important to know the incidence of liver adenylate kinase in serum, because this isoenzyme is inhibited only to 50% by 10 tmol of diadenosine pentaphosphate per liter ( Figure 2 ). We measured the adenylate kinase activity in sera of patients with various liver diseases. Table 1 presents a representative selection of our determinations. In acute hepatitis (patients 1-4) residual adenylate kinase activity, measured in the presence of 25 mol of diadenosine pentaphosphate per liter, usually remained below 10 U/liter. We obtained similar results for five patients with chronic liver diseases (patients 5-9). In these patients (patients 1-9) we saw no correlation between the activity of adenylate kinase and of other enzymes, except for glutamate dehydrogenase.
The coincidence of the significant increase in glutamate dehydrogenase and adenylate kinase activity in patient 10 (Table 1) prompted us to further investigations. The predictive value of glutamate dehydrogenase activity could be indeed confirmed: highly increased glutamate dehydrogenase activities, above 100 U/liter, usually coincide with abnormal liver adenylate kinase values. In serum we found residual adenylate kinase activities between 10 and 70 U/liter, and in one patient, with acute congestion of the liver, the activity was 431 
Inhibition of Adenylate Kinase by AMP
To a human serum pool with low creatine kinase activity (34 U/liter at 25 #{176}C) we added increasing amounts of hemolysate. We measured adenylate kinase activity with our standard reagent for creatine kinase assay (13), except that we omitted creatine phosphate and varied the AMP concentration.
Thus the activities obtained correspond to the sample blank values of the creatine kinase assay. The adenylate kinase activity, without AMP in the assay mixture, proportionally increased with the portion of hemolysate in the sample (Figure 3 In another experiment, we added increasing amounts of purified adenylate kinase from rabbit muscle to the same serum pool, and measured adenylate kinase activity as specified above. The inhibitipn pattern was almost identical with that of the erythrocyte enzyme (Figure 4) . The residual activities amounted to about 50, 25, 15, and 8% at 1, 3, 5, and 10 mmol of AMP per liter.
Inhibition of adenylate kinase by AMP depends on the ADP concentration ( Figure 5 ). At 1 mmol of ADP per liter, residual activities measured in the presence of 1 mmol and 3 mmol AMP per liter, were only 38% and 18%, respectively, as compared to 51% and 22% at 2 mmol of ADP per liter. At 5 mmol and 10 mmol of AMP per liter, lesser differences were observed. These values were essentially confirmed on using specimens from other patients.
Inhibition of Creatine Kinase by AMP
Creatine kinase activity was measured in nonhemolyzed sera in the presence of 2 mmol of ADP per liter and at various AMP concentrations.
At each AMP concentration the individual sample blanks were also measured in the absence of creatine phosphate, starting the reaction with ADP. "True" creatine kinase activities were calculated by subtraction of the individual sample blanks. The inhibition of the "true" creatine kinase activity averaged 3, 5, 10, 17, and 30% at 3,5, 10, 20, and 40 mmol AMP per liter, respectively.
Clearly, the inhibition depended on the AMP:ADP molar ratio. At a ratio of 5, e.g., it amounted to about 10%, independent of the actual molar concentration of the compounds (5:1 or 10:2). In accordance with this, AMP showed a competitive inhibition pattern with ADP in the Dixon plot (not illustrated), the K, for AMP being about 10 mmol/liter at 25 #{176}C. On the other hand, with creatine phosphate as the variable substrate, AMP gives an uncompetitive inhibition pattern. We have not invested more work in the study of the nature of creatine kinase inhibition by AMP because of its minor practical significance for creatine kinase assay.
Inhibition of Adenylate Kinase by Diadenosine Pentaphosphate
Human erythrocyte adenylate kinase was strongly inhibited by diadenosine pentaphosphate ( Figure 1 ). As in the inhibition experiments with AMP, we enriched a human serum pool with increasing amounts of hemolysate. Inhibition averaged 45, 90, 94, and 97% at 0.2, 2, 5, and 10 tmol of diadenosine pentaphosphate per liter. The pattern of inhibition of rabbit muscle adenylate kinase by diadenosine pentaphosphate was almost the same.
In contrast, adenylate kinase from human liver was relative weakly inhibited by diadenosine pentaphos- Figure 6 , were 28 nmol of diadenosine pentaphosphate per liter for adenylate kinase from human erythrocytes but 2.9 tmol of diadenosine pentaphosphate per liter for human liver adenylate kinase.
Inhibition of Creatine Kinase by Diadenosine Pentaphosphate
Creatine kinase activity was measured in eight nonhemolyzed sera (75-260 U/liter at 25 #{176}C) with our standard reagent (13) containing diadenosine pentaphosphate in various concentrations (0, 10, 100,500, and 1000 izmol/liter). Up to a concentration of 100 zmol of diadenosine pentaphosphate per liter we observed no inhibition of the "true" creatine kinase activity at all. Inhibition ranged from 0-3%, and 1-5% at 500 and 1000 mol of diadenosine pentaphosphate per liter of assay mixture, respectively.
As in the inhibition study with AMP, the "true" creatine kinase activities were calculated by subtraction of the individual sample blanks.
Effect of Inhibitors on the Sample Blank of the Creatine Kinase Assay
The sample blanks were measured without and with inhibitors at 25 #{176}C and 37 #{176}C, omitting creatine phosphate from the standard creatine kinase reagent (13). Five millimoles of AMP per 100 ml of assay mixture decreased sample blank rates by at least half in nonhemolyzed sera from patients, even those with normal enzyme profiles (Table  2) . Additional diadenosine pentaphosphate (10 molfliter) did not influence the mean sample blank. In one serum the sample blank decreased in the sequence: 27 U/liter without inhibitor, 15 U/liter with AMP, and 8 U/liter in the presence of both inhibitors. The presence of muscle adenylate kinase in this sample seemed unlikely because the creatine kinase activity was normal (23 U/liter at 25 #{176}C). We assume that erythrocyte adenylate kinase was present, although this group comprised only sera without visible hemolysis. This phenomenon was sporadically but repeatedly observed.
At 37 #{176}C, sample blank values were about twice as high as at 25 #{176}C. Even in the absence of visible hemolysis and without any inhibitors, values as high as 40-GO U/liter were observed. These blank values, found in 10 sera, were decreased by the presence of 5 mmol of AMP per liter to 9-14 U/liter. Additional diadenosine pentaphosphate (10 tmol/liter) further decreased the blank rates to 4-7 U/liter.
The sample blanks could be significantly decreased also in sera of patients with muscle damage (creatine kinase: 110-1630 U/liter at 25 #{176}C) and liver diseases (pathological liver enzyme profile) by the use of inhibitors. If both inhibitors were included, there was an additional decrease in the sample blank of sera containing muscle adenylate kinase. As expected, no effect at all was observed by additional diadenosine pentaphosphate on the sample blank of sera with liver adenylate kinase (Table 2) .
The usefulness of the inhibitor mixture was further elucidated for sera with even faint hemolysis. Addition of 10 imol of diadenosine pentaphosphate per liter decreased the sample blank by almost half as compared with the sample blank measured only in the presence of 5 mmol of AMP per liter (Table 2) .
In another experiment at 25 #{176}C, increasing amounts of hemolysate were added to a serum with low creatine kinase activity. The effect of hemolysis on the sample blank and on the apparent creatine kinase activity is demonstrated in Figure 7 . Both the sample blank and the apparent creatine kinase activity simultaneously increased with the ratio of hemolysate. AMP greatly diminished interference from erythrocyte adenylate kinase, but the residual activity (about 15%) could lead 
Discussion
Our experiments
confirm the significant effect of adenylate kinase on the creatine kinase activity measurement (2) and emphasize the need to suppress it. Interference from adenylate kinase can be blanked out by an individual sample blank in which creatine phosphate is omitted from the reagent (10), but this procedure not only doubles the workload but also diminishes the precision of the assay because the imprecision of both analysis and blank will influence the final result. That is why most authors prefer to inhibit adenylate kinase with AMP (1, 6-9). Oliver (1) found that adenylate kinase is completely inhibited when the AMP concentration is 10-fold that of ADP. This AMP:ADP ratio was also considered to be satisfactory by other investigators (6) (7) (8) 15) . Inhibition of creatine kinase by AMP was generally assumed to be negligible (1, 6, 15) ; only Hess et a!. (10) described a marked inhibition, at an AMP:ADP ratio of 10:1.
In our study, the sample blank of hemolyzed sera containing 1 g of hemoglobin per liter had an apparent creatine kinase activity of about 100 U/liter at 25 #{176}C. This value could be significantly decreased by incorporating AMP in the reagent. AMP competitively inhibits adenylate kinase. The association constants for the binding of AMP to adenylate kinase ranged around 0.3 mmol/liter and were not significantly different for the erythrocyte and liver enzyme. Adenylate kinase was 95% inhibited at an AMP:ADP ratio of 10:1, but creatine kinase was simultaneously inhibited by 15-20%. At the AMP:ADP ratio of 5:2 we recommend (13) the inhibition of creatine kinase is still about 5%, but ipterference by adenylate kinase is decreased to only 10-15%.
A very promising alternative to AMP seemed to us to be diadenosine pentaphosphate (2) as inhibitor of adenylate kinase in the creatine kinase assay. We confirmed the high inhibitory efficacy of this compound on adenylate kinase from erythrocytes and muscle. Adenylate kinase from human erythrocytes and rabbit muscle was almost completely inhibited already at 10 mol of diadenosine pentaphosphate per liter, whereas creatine kinase was not affected at all by this compound up to 100 mol per liter. The inhibitory power on human liver adenylate kinase was less marked. Even at 100 mol of diadenosine pentaphosphate per liter we observed a residual activity of about 20%. For complete inhibition, concentrations of 500-1000 tmol/liter are necessary. Accordingly the K1 value was 100-fold higher for the liver enzyme than for the erythrocyte enzyme.
These results raised the question about the prevalence and extent of liver adenylate kinase activity in serum-i.e., how concerned one should be about interference with the creatine kinase determination. Data on adenylate kinase in liver diseases are scarce (5); we could find no information on the liver isoenzyme in serum. In serum from cases of acute and chronic liver diseases, we saw residual activities of as much as 10 U/liter when 25 zmol of diadenosine pentaphosphate per liter was incorporated in the reagent. Moreover, acute liver cell damage, indicated by marked increase in the activity of glutamate dehydrogenase, an enzyme exclusively localized in the mitochondria (16), coincided with a significant increase in liver adenylate kinase. We measured residual activities as great as 70 U/liter-and in one case with acute congestion of the liver even 431 U/liter-with a reagent containing 25 omol of diadenosine pentaphosphate per liter.
To summarize: Diadenosine pentaphosphate appears to be an ideal inhibitor for the muscle and erythrocyte type of isoenzymes of adenylate kinase. Unfortunately, the liver enzyme is less suppressed, and relative high activities may be expected in cases with acute liver cell damage. The use of diadenosine pentaphosphate alone in a sufficiently high concentration was precluded because this compound is very expensive. On the other hand, with AMP alone and an AMP:ADP molar ratio of 5:2, adenylate kinase will be inhibited only to 80-85% independently of the isoenzyme composition. A further increase in AMP concentration would increase the inhibition of creatine kinase. The combination of both inhibitors, however, appears to be a good choice.
Note added in proof: After this manuscript had been submitted Rosano et al. [Gun. Chem. 22, 1078 (1976 ] recommended sodium fluoride as inhibitor of adenylate kinase in the creatine kinase assay. In our experiments, 25 mmol of fluoride per liter assay mixture inhibited adenylate kinase from human erythrocytes to 92% and from human liver to 83% after a lag phase of 4 mm at 30 #{176}C as recommended by Rosano et al. The rate of inhibition increased until a lag phase of 6-8 mm and amounted to 95% or 88%, respectively.
We simultaneously found a mean inhibition of creatine kinase of 6% in 18 human sera (creatine kinase activity: 60-320 U/liter at 30 #{176}C) by 25 mmol of fluoride per liter.
Another attempt to omit AMP completely failed also. 
